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SUMMARY
Background
Early detection and treatment of colorectal adenomatous polyps (AP) and
colorectal cancer (CRC) is associated with decreased mortality for CRC.
However, accurate, non-invasive and compliant tests to screen for AP and
early stages of CRC are not yet available. A blood-based screening test is
highly attractive due to limited invasiveness and high acceptance rate
among patients.
Aim
To demonstrate whether gene expression signatures in the peripheral blood
mononuclear cells (PBMC) were able to detect the presence of AP and
early stages CRC.
Methods
A total of 85 PBMC samples derived from colonoscopy-veriﬁed subjects
without lesion (controls) (n = 41), with AP (n = 21) or with CRC (n = 23)
were used as training sets. A 42-gene panel for CRC and AP discrimina-
tion, including genes identiﬁed by Digital Gene Expression-tag proﬁling of
PBMC, and genes previously characterised and reported in the literature,
was validated on the training set by qPCR. Logistic regression analysis fol-
lowed by bootstrap validation determined CRC- and AP-speciﬁc classiﬁers,
which discriminate patients with CRC and AP from controls.
Results
The CRC and AP classiﬁers were able to detect CRC with a sensitivity of 78%
and AP with a sensitivity of 46% respectively. Both classiﬁers had a speciﬁcity
of 92% with very low false-positive detection when applied on subjects with
inﬂammatory bowel disease (n = 23) or tumours other than CRC (n = 14).
Conclusion
This pilot study demonstrates the potential of developing a minimally inva-
sive, accurate test to screen patients at average risk for colorectal cancer,
based on gene expression analysis of peripheral blood mononuclear cells
obtained from a simple blood sample.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common can-
cer and second-leading cause of cancer-related death
among men and women in Europe1 and it fulﬁls the
World Health Organisation (WHO) criteria for mass
screening.2 Importantly, CRC is often curable, when diag-
nosed at early stages. Moreover, adenomatous polyps
(AP) detection and removal prevents CRC formation and
decreases mortality due to CRC. Screening modalities for
CRC have already been adopted by several countries, and
clinical practice guidelines recommend that average-risk
individuals begin regular screening at the age of 50.3
Colonoscopy is the ‘gold standard’ for CRC diagnosis;
however, it is not the preferred method for screening
because of its cost, invasiveness, low compliance and lim-
ited accessibility. Currently recommended non-invasive
methods for mass screening include immunochemical
and guaiac faecal occult blood testing (iFOBT, gFOBT).
Yet, compliance with faecal tests is still suboptimal in
countries with an FOBT screening program.4–6 Therefore,
there is still a large unmet screening need calling for a
non- or minimally invasive, compliant, cost-effective and
accurate test to detect AP and CRC at early stages.
A blood-based screening test is highly attractive due
to its minimal invasiveness and high acceptance among
patients. Several attempts have been made in the past to
search for tumour markers in the blood to develop
screening tests for CRC.7–9 However, validation data
obtained from a large screening-eligible population are
still missing or showed mitigated test performances.10
Searching for blood-borne tumour markers could lever-
age different concepts such as the release of tumour-der-
ived molecules (proteins, nucleic acids) into the blood
stream, the presence of circulating tumour cells or the
generation of a host response to tumour-derived signals.
The latter is supported by the evidence that solid malig-
nancies, to progress to clinically relevant tumours, require
support from the tumour microenvironment, in particular
from tumour-mobilised bone marrow-derived cells
(BMDC).11, 12 Tumour-recruited BMDC are likely to ini-
tiate differentiation and effector programs during their
mobilisation from the bone marrow, which might be
detectable during their transition in the blood.13, 14 The
report of signatures derived from peripheral blood mono-
nuclear cells (PBMC) gene expression proﬁles and associ-
ated with breast,15 renal,16, 17 pulmonary,18 bladder19 and
digestive cancers8, 9, 20 further corroborates these obser-
vations. The aim of this study was to demonstrate
whether the feasibility of identifying gene expression
signatures in PBMC was able to discriminate patients
with AP and CRC from subjects without these lesions.
Moreover, we wanted to deﬁne predictive classiﬁers that
could correctly classify Control, AP and CRC samples.
METHODS
Subjects
Participants in this monocentric case–control study were
recruited from the Endoscopy Unit and from Urology,
Gynecology, Pulmonary and Surgery units of the Centre
Hospitalier Universitaire Vaudois (CHUV), Lausanne,
Switzerland between March 2007 and March 2009. They
included subjects without any colon lesion (control group)
(n = 41), patients with adenoma (AP group) (n = 21) or
colorectal carcinoma (CRC group) (n = 23). In addition,
patients with inﬂammatory bowel disease (IBD) (n = 23)
were also recruited. All these subjects underwent colonos-
copy examination. In addition, patients with diagnosed
tumours other than CRC (n = 14) were included to test the
sensitivity of our classiﬁers to non-CRC tumours. These
patients were not assessed by colonoscopy. Blood from all
subjects was drawn before or immediately after colonos-
copy, but before polypectomy or biopsy. The exclusion cri-
teria included: age <18 years, alcohol or drug abuse, severe
cardio-respiratory, liver, renal or gastrointestinal diseases,
Hereditary Non Polyposis Colon Cancer (HNPCC) or
Familial Adenomatous Polyposis (FAP). For the control,
CRC and AP group, the concomitant presence of IBD or a
malignant tumour other than CRC was also an exclusion
criterion. Subjects signed a written informed consent before
entering the study. The study was performed in accordance
with the ethical principles of the Declaration of Helsinki
and Good Clinical Practice guideline and was approved by
the ethical committee of the Canton Vaud.
PBMC separation and RNA extraction
Blood was collected in 4 9 5 mL heparin tubes (Vacu-
tainer, Becton Dickinson, Basel, Switzerland). PBMC
separation was performed within 6 h using Hist-
opaque®-1077 (Sigma-Aldrich, Buochs, Switzerland).
RNA was extracted with the RNeasy Mini Kit (Qiagen,
Basel, Switzerland); DNase was treated according to the
manufacturer’s instructions and stored at 80 °C.
Digital gene expression (DGE)-tag proﬁling and data
analysis
Tag proﬁling libraries were prepared and sequenced at
Fasteris SA (Plan-les-Ouates, Switzerland) using the
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Illumina NlaIII DGE protocol and the Illumina Genome
analyzer II, starting from 1 lg of total RNA. Tag align-
ment to a reference genome and tag counting were per-
formed with GeneSifter Analysis edition software
(Geospiza-Perkin Elmer, Oftringen, Switzerland). After
mapping and counting, a gene list with digital gene
expression values was available for each sample. Norma-
lised gene expression was calculated by multiplying each
value with a linear scaling factor that was deﬁned as the
total number of tag reads obtained for a certain sample
divided by the average number of tag reads obtained in
all samples.21
Normalised data were log2 transformed, and Wilco-
xon rank test, Negative binomial distribution22, 23 and
nonparametric t statistics24 were used to identify differ-
entially expressed genes. All statistical analyses were per-
formed with R software (R-CRAN free software
environment for statistical computing and graphics).
Three-dimensional principal component analysis
(PCA), performed with Partek Discovery Suite, was
used to easily visualise the multi-dimensional PCR-der-
ived data and reveal the internal structure of the data in
a way that best explains the variance in the data. It was
not used as a tool for gene selection.
Reverse transcription and single-channel quantitative
multiplex PCR (scqmPCR)
200 ng of total RNA was reverse transcribed into cDNA
in a ﬁnal volume of 20 lL containing 4 U of Omniscript
reverse transcriptase (Qiagen) in the manufacturer’s buf-
fer, 0.5 mmol/L of each dNTP, 10 U RNase inhibitor
(Promega, D€ubendorf, Switzerland) and 1 lmol/L NVd
(T)’s (5′TTTTTTTTTTTTTTTTTTTVN3′).
A modiﬁed version of the single-channel quantitative
multiplex PCR (scqmPCR) described by Therianos et al.25
was used. The ﬁrst step of the scqmPCR consisted of the
pre-ampliﬁcation of the target sequences. Each 100 lL of
the PCR reaction contained 2 lL of cDNA or plasmid,
1 U of HotStarTaq Plus DNA polymerase (Qiagen) in the
manufacturer’s buffer, 0.2 mmol/L of each dNTP and
15 lL of primer mixture. The primer mixture consisted of
forward and reverse primers for a deﬁned subset of the
genes of interest, at a ﬁnal concentration of 2 lmol/L
each. The 106 different primer pairs (103 target genes and
3 reference genes) were equally split into three different
primer mixtures. The PCR program consisted of 15 min
at 95 °C to activate the polymerase, followed by 10 cycles
of 30 s of denaturation at 95 °C, 30 s of annealing at
60 °C and 30 s of extension at 72 °C, and a ﬁnal step of
extension of 3 min at 72 °C.
The second, quantitative step of the scqmPCR was
performed with 96-well plates loaded on the StepOne-
Plus real-time PCR instrument (Applied Biosystem, Zug,
Switzerland). Each 20 lL of PCR reaction contained
1 lL of the ﬁrst round scqmPCR reaction, 0.2 lmol/L of
forward and reverse primer for one target gene, and the
KAPA SYBR Green Fast qPCR Master Mix (Kapa Biosys-
tems, Labgene Scientiﬁc, Cha^tel-St-Denis, Switzerland).
Real-time PCR program consisted of 2 min at 95 °C for
the Taq DNA Polymerase activation and 40 cycles of 3 s
at 95 °C and 20 s at 60 °C. A melting curve analysis was
performed to verify the speciﬁcity of each ampliﬁcation
product. All reactions were performed in duplicates. The
StepOnePlus 2.1 software was used for the Ct determina-
tion, using a manually set threshold of 0.1 for all the PCR
runs. Copy number values for each transcript were
calculated by reference to standard curves. 10-fold serial
dilutions of target-speciﬁc plasmids, ranging from
1 000 000 copies to 10 copies, were used to determine
the linear relationship between copy number and Ct.
The normalised copy numbers were obtained by
dividing the gene copy number by the median copy
number of three housekeeping genes, RPLP0, NACA,
B2M multiplied by a 105 factor.
PCR primers were designed using Primer3 software
(available at http://www-genome.wi.mit.edu/genomesoft-
ware/other/primer3.html) to speciﬁcally amplify between
180 and 200 base pairs for the target genes (Table S1).
Statistical analysis
In the gene selection phase, several univariate (t-test, Wil-
coxon rank test26 and univariate logistic regression27, 28)
and multivariate statistical methods (classiﬁcation and
regression tree,29 logistic regression27, 28 and top scoring
pair30) were applied on normalised PCR-derived gene
expression values. All test results for each gene were sum-
marised into a score and used for selecting the genes with
the highest power in group discrimination (data not
shown). This multi-test approach was chosen to maximise
the capture of the information carried by the genes.
In the modelling phase, penalised logistic regression
models31, 32 were ﬁtted on two subsets of the training
set, one including all CRC patients and controls and one
including all adenoma patients and controls, and two
different classiﬁers were established, the CRC and AP
classiﬁer respectively.
Fitted models were validated by non-overlapped boot-
strap method33: 500 random data sets were drawn with
replacement from training set; each bootstrap had the
same size as the training set. The model was re-ﬁtted at
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each bootstrap and validated with the out-of-bag samples.
The speciﬁcity and sensitivity average values over 500
bootstraps were calculated and Receiver Operating Char-
acteristics (ROC) curves were generated. All analyses were
performed with R software unless otherwise indicated.
RESULTS
Characteristics of the study population
Clinical and demographic characteristics of the study
population are summarised in Table 1. The study was
not designed to be age-matched; therefore, differences
were present between the age of control and case groups.
The study population included 41 colonoscopy-veriﬁed
controls, 21 patients with adenomas and 23 patients with
colorectal cancer. The great majority of patients in the
AP group had advanced adenomas (17/21), being larger
than 1 cm or having a villous component, and the
greater part of CRC were at an early stage (Table 1).
Adenomas and CRCs were mainly located in the left
colon (62% and 77%, respectively, Table S2A), thereby
reﬂecting the typical enrichment of these pathologies in
the lower third of the colon. Moreover, 14 patients with
malignant tumours other than CRC and 23 IBD patients
were recruited and included in the study as separate
groups (Table 1, Table S2B, S2C).
Biomarker identiﬁcation
Biomarker candidates were identiﬁed through two differ-
ent approaches (Figure 1). In a ﬁrst candidate marker
approach, we reviewed literature for potential biomarkers
associated with CRC and we mined unpublished micro-
array-based gene expression data, previously generated in
our laboratory (C. R€uegg, unpublished results). This
approach led to the selection of a panel of 49 candidate
biomarkers related to angiogenesis and colorectal cancer
to be further evaluated by PCR. In a second, comple-
mentary approach, we conducted a whole-transcriptome
analysis of a subset of the study population, i.e. 33
PBMC samples from 16 control subjects, 13 patients
with adenoma and from 4 patients with CRC, by DGE-
tag proﬁling. This method entails the capture of a
17-nucleotide (nt) sequence immediately downstream of
the 3′-most NlaIII site in each polyadenylated RNA.
These 17 nt ‘tags’ are sequenced in a high-throughput
manner and the number of occurrences of each unique
tag is counted, resulting in digital gene expression
Table 1 | Clinical and demographic characteristic of
the study population
Patients (n)
Age (years) mean
/median (min-max) Male
Controls 41 52/56 (21–85) 39%
Adenomas 21 68/67 (48–84) 52%
Advanced 17
<5 mm 4
CRC 23 65/62 (30–88) 52%
I 6
II 6
III 5
IV 2
Unknown Stage 4
IBD 23 42.5/40 (25–70) 52%
Crohn’s disease 16
Ulcerative colitis 6
Behcet 1
Other cancers 14 65/66 (54–77) 71%
Prostate 8
Lung 4
Breast 1
Pancreas 1
CRC, colorectal cancer; IBD, inﬂammatory bowel disease.
Candidate approach
49 genes
Literature review
Microarray data
Whole transcriptome
analysis
54 genes
DGE tag profiling (n = 33)
Quantitative PCR validation
103 candidate genes
n = 88 
Univariate and multivariate statistical 
analysis
42 genes
Logistic regression analysis
Controls vs CRC
Controls vs AP
CRC classifier
4 genes
AP classifier
8 genes
Figure 1 | Classiﬁers deﬁnition workﬂow. After the
identiﬁcation of a pool of 103 potential biomarkers by
two complementary approaches, the marker pool
underwent validation by quantitative PCR. Statistical
analysis retained 42 genes that were used to ﬁt logistic
regression models and generate a CRC and an AP
classiﬁer. DGE, digital gene expression; CRC, colorectal
cancer; AP, adenomatous polyp.
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proﬁles where tag counts reﬂect expression levels of the
corresponding transcript.34
A total of 20 288 unique gene transcripts with a tag
count greater than 1 were identiﬁed. The transcripts
showing a median count equal to zero across all samples
were ﬁltered out. The remaining 8843 genes underwent
differential gene expression analysis based on signiﬁcant
p value (<0.05) and a gene expression fold change
greater than 2 between control and case groups. Eight-
y-eight genes were identiﬁed as signiﬁcantly overrepre-
sented or underrepresented in the adenoma group
compared with the control group, and 54 were retained
for PCR validation based on gene function and overall
expression levels (data not shown).
PCA was applied to the 54-gene data set to visualise in
a three-dimensional space the overall variability in
the data (Figure 2). Controls, adenomas and CRC samples
showed distinct spacial distribution with few overlaps, sug-
gesting that they possess speciﬁc gene expression patterns.
Biomarker validation by quantitative PCR
A total of 103 potential biomarkers identiﬁed by candidate
gene approach and by whole-transcriptome analysis
(Table S1) were subjected to scqmPCR validation on
PBMC samples derived from control (n = 41), adenoma
(n = 24) and CRC (n = 23) patients (Figure 1). Univari-
ate analysis identiﬁed 24 genes with signiﬁcant test
(P < 0.05) and gene expression fold change greater than
1.5 between the control and adenoma or carcinoma
groups (Table 2). Most of the genes showed up-regulation,
whereas only two genes were down-regulated (BANK1,
VPS18), conﬁrming the ﬁndings from the tag proﬁling
and the literature. In general, genes were able to discrimi-
nate both adenoma and CRC groups from the controls,
although with lesser power for the adenoma group. CTSL1
was the gene most signiﬁcantly up-regulated in the CRC
group compared with the control group. ITIH4 and TUG1
were the genes most signiﬁcantly up-regulated in the ade-
noma group compared with the control group. Only two
genes (LST1 and TRIM24) were speciﬁcally signiﬁcant for
the discrimination of the adenoma group. In the CRC
group, the two genes were also up-regulated, but statistical
signiﬁcance did not reached the cut-off value, although it
was very close to. This suggests that LST1 and TRIM24
expression in cancer patients is more heterogeneous than
in adenoma ones, possibly depending on disease stage,
rather than a full down-regulation of the genes as the dis-
ease progress from benign to malignant.
In order not to miss genes that might have a discrimi-
natory power only when used in combinations, we con-
ducted a multivariate analysis of the 103 genes. Eighteen
genes that were not initially retained after the univariate
analysis were additionally identiﬁed as signiﬁcant by this
analysis (data not shown, Table S1). In conclusion, a
total of 42 biomarkers were validated by scqmPCR and
retained for the subsequent modelling phase (Figure 1).
Interestingly, functional analysis performed with Inge-
nuity Pathway Analysis software (Table 3) revealed that
some of these genes were associated with inﬂammatory
conditions. Moreover, the 42-gene panel is enriched in
genes involved in leucocytes trafﬁcking, suggesting that
up-regulation of these genes in patients may reﬂect an
increased or speciﬁc capacity of colorectal tumours to
attract monocytes/macrophages. Taken together, the
results of this analysis support the notion that CRC is
able to elicit an inﬂammatory-like reaction in circulating
PBMC.
Discriminatory power of predictive classiﬁers
The 42-gene data set was utilised to generate predictive
models. Two sample subsets, controls and adenomas or
controls and CRCs, were used to deﬁne an AP classiﬁer
and a CRC classiﬁer. Penalised logistic regression models
Control
CRC
AP
PC 1
PC
 2
PC
 3
Figure 2 | Three-dimensional PCA of the 54
differentially expressed genes identiﬁed from the
DGE-tag proﬁling data. PBMC samples from adenoma
patients (n = 13) are represented by red dots, from
CRC patients (n = 4) by orange dots and from control
subjects (n = 16) by grey ones.
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were ﬁtted on these two subsets and validated by bootstrap
(Figure 1). The two best classiﬁers were identiﬁed as follow:
AP classiﬁer:
log
Prðyi ¼ 1Þ
1 Prðyi ¼ 1Þ
 
¼ 3:959þ 0:061 GKþ 0:10
MMP9þ 0:053 TRIM24
þ 0:081 TUG1
CRC classiﬁer:
log
Prðyi ¼ 1Þ
1 Prðyi ¼ 1Þ
 
¼ 4:42 0:06 BANK1þ 0:162
 CDAþ 0:29 CTSL1þ 0:121
 GKþ 0:094MMP9þ 0:034
 PECAM1þ 0:005 PIP4K2B
þ 0:046 TUG1
Table 2 | Differentially expressed genes among control, AP and CRC groups determined by univariate analysis of the
quantitative PCR data set. t-test P values were representative of the univariate analysis and therefore reported in the
table
Gene Name Description Discovery
t-test P value
(AP vs. Con)
t-test P value
(CRC vs. Con)
Fold Change
(AP/Con)
Fold Change
(CRC/Con)
CTSL1 Cathepsin L1 DGE 0.043 9.40E-05 4.42 9.10
GK Glycerol kinase DGE 0.006 0.0002 3.83 3.96
CDA Cytidine deaminase Literature8 0.018 0.00047 1.49 1.77
SET SET translocation (myeloid
leukaemia-associated)
DGE 0.070 0.001 4.06 2.37
PFDN5 Prefoldin subunit 5 DGE 0.082 0.002 3.88 2.43
PECAM1 Platelet/endothelial cell adhesion
molecule 1 (CD31 antigen)
DGE 0.013 0.0017 3.46 3.09
APOBEC3A Apolipoprotein B mRNA
editing enzyme,
catalytic polypeptide-like 3A
DGE 0.196 0.002 2.37 2.50
UBXD5 UBX domain containing 5 DGE 0.0494 0.002 4.47 3.48
MSL1 Male-speciﬁc lethal-1 homolog DGE 0.078 0.002 3.04 3.98
MMP9 Matrix metallopeptidase 9 (gelatinase
B, 92 kDa gelatinase, 92 kDa type
IV collagenase)
Literature43 0.007 0.0030 1.60 3.97
BANK1 B-cell scaffold protein with
ankyrin repeats 1
Literature8 0.405 0.003 2.14 4.80
C9orf78 Chromosome 9 open
reading frame 78
DGE 0.082 0.003 3.42 2.80
VPS18 Vacuolar protein sorting 18
homolog (S. cerevisiae)
DGE 0.876 0.004 2.52 5.51
ISCU Iron-sulphur cluster scaffold
homolog (E. coli)
DGE 0.191 0.006 2.91 2.67
DYNC1LI2 Dynein, cytoplasmic 1, light
intermediate chain 2
DGE 0.031 0.006 4.15 2.14
DYM Dymeclin DGE 0.013 0.0070 3.50 3.16
PIP4K2B Phosphatidylinositol-5-phosphate
4-kinase, type II, beta
DGE 0.016 0.009 4.17 2.34
TUG1 Taurine up-regulated gene 1 DGE 0.006 0.023 5.35 1.87
EPHX2 Epoxide hydrolase 2, cytoplasmic DGE 0.056 0.026 3.19 3.66
ITIH4 Inter-alpha (globulin) inhibitor
H4 (plasma
Kallikrein-sensitive glycoprotein)
DGE 0.026 0.028 5.48 1.71
CDCA4 Cell division cycle associated 4 DGE 0.085 0.035 2.58 1.80
S100A8 S100 calcium-binding protein A8 Literature48 0.159 0.047 1.32 2.11
LST1 Leucocyte-speciﬁc transcript 1 DGE 0.008 0.069 3.52 1.59
TRIM24 Tripartite motif-containing 24 DGE 0.007 0.077 2.19 3.20
DGE, digital gene expression; AP, adenoma; CON, control; CRC, colorectal cancer.
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with yi being either 0 or 1 according to the pre-deﬁned
classiﬁcation groups.
The bootstrap validation showed for the CRC classiﬁer
an average sensitivity and speciﬁcity of 78% and 92%,
and for the adenoma classiﬁer an average sensitivity and
speciﬁcity of 46% and 92% respectively. ROC analysis
determined an average area under the curve (AUC) of
0.91 (0.83–0.98, 95% CI) for the CRC classiﬁer and an
average AUC of 0.76 (0.59–0.88, 95% CI) for the AP one
(Figure 3a and b).
Classiﬁers performance in other diseases
The speciﬁcity of the two predictive classiﬁers was inde-
pendently evaluated in subjects with IBD. The CRC and
AP classiﬁers showed a speciﬁcity of 91% (2/23) and
96% (1/23) towards IBD respectively. Subjects with
malignant tumours other than CRC were also tested to
verify the sensitivity of the two classiﬁers towards
tumours other than CRC. None of these subjects were
classiﬁed as CRC or AP by our classiﬁers, suggesting that
both classiﬁers are highly speciﬁc to colorectal tumours.
Unfortunately, these subjects could not be assessed by
colonoscopy and therefore the concomitant presence of
colorectal lesions could not be formally excluded. For
this reason, they were not used as an independent set to
assess the classiﬁers speciﬁcity.
DISCUSSION
The aim of the study was to identify PBMC-derived bio-
markers and to develop predictive classiﬁers, which are
able to discriminate patients with CRC and AP from
healthy controls. The lack of non-invasive detection tools
for the adenoma prompted us to focus our study not
only on the identiﬁcation of speciﬁc biomarkers/
Table 3 | Functional analysis of the 42 biomarkers selected for the modelling phase. The table reports the most
signiﬁcantly represented biological functions and diseases within the 42-biomarker panel. P values measure the
likelihood that the association between a set of biomarkers and a given IPA functional category is random. The
number of genes associated with a speciﬁc function is reported in the last column. The analysis was performed with
the Ingenuity Pathway Analysis (IPA) software
Category Diseases or functions P value Number of genes
Inﬂammatory and immunological disease Rheumatic disease, arthritis,
systemic autoimmune syndrome,
lupus erythematosus
7.99E-07 17
Immune cell trafﬁcking and haematological
system development/function
Phagocyte migration and
transmigration
3.13E-04 4
Cellular growth and proliferation Cell proliferation 6.01E-04 20
Dermatological diseases Psoriasis 6.02E-04 10
Inﬂammatory response Organ inﬂammation 9.43E-04 10
Cell death and survival Cell death 1.04E-03 18
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Figure 3 | Receiver Operating Characteristics (ROC)
analysis of the CRC (a) and the AP classiﬁers (b) using
500 bootstraps validation. The boxplots represent the
distribution of the 500 bootstraps. The black line
represents the average values over 500 bootstraps for
clinical speciﬁcity and sensitivity.
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classiﬁers for CRC but also for those speciﬁc for adeno-
matous polyps, the main precursor lesion of CRC.
In particular, the biomarker discovery approach based
on whole-transcriptome analysis was conceived with this
goal in mind and this was reﬂected by the inclusion of
samples issued almost exclusively from adenoma patients.
Using combined candidate and whole-transcriptome
approaches, we identiﬁed and validated by quantitative
PCR a set of 42 genes that are able to discriminate between
the control group and the CRC or AP group. Speciﬁc bio-
marker combinations for CRC and AP discrimination
were determined by logistic regression analysis, resulting
in an eight- and four-gene predictive classiﬁer respectively.
With a speciﬁcity of 92%, the CRC classiﬁer showed a sen-
sitivity of 78% and the AP classiﬁer a sensitivity of 46%.
The early stage of development of our test does not yet
allow a full comparison with existing screening methods.
Nevertheless, it is of interest to note that the adenoma
detection rate (46%) was superior to the ones reported for
faecal immunochemical testing (FIT, 20%-29%),35, 36 or
for new tests such as the Septin 9 test (11%).10
Our biomarker discovery approach identiﬁed new can-
didate genes, as well as it conﬁrmed already known CRC
biomarkers. In particular, TUG1, TRIM24, PIP4K2B,
GK, among the novel ones and BANK1, CDA, PE-
CAM1/CD31, CTSL1, MMP9 among the known ones
were identiﬁed by our eight- and four-gene classiﬁers as
the most discriminant markers.
TUG1 (Taurine Up-regulated Gene 1) is a long inter-
genic noncoding RNAs, a class of noncoding RNAs that
regulate gene expression via chromatin reprogramming.
Besides its role in retina development,37 little is known
about its function, including in leucocytes. Recently, it
was shown that it was up-regulated in urothelial carci-
noma of the bladder and that silencing of TUG1 inhib-
ited cell proliferation and induced apoptosis in urothelial
carcinoma cells.38
TRIM24, also known as HTIF1 alpha, functions as a
co-regulator that positively or negatively modulates the
transcriptional activities of several nuclear receptors,
including estrogen receptor, retinoic acid receptor, and
of p53. TRIM24 is overexpressed and associated with
poor prognosis in breast cancer39 and head and neck
squamous cell carcinoma,40 and in nonsmall cell lung
carcinoma, TRIM24 overexpression correlates with
tumour progression.41 Interestingly, TRIM24 is expressed
in blood cells and it was suggested to play a role in mye-
loid differentiation. In particular, its down-regulation in
immature myeloid cells was required for monocyte-mac-
rophage maturation.42
MMP9 is a proteolytic enzyme produced by inﬂam-
matory cells, promoting tumour progression by remodel-
ling the extracellular matrix and basal membranes and
favouring tumour angiogenesis. MMP-9 is strongly
expressed in colorectal cancer with a signiﬁcantly higher
expression in high-grade adenoma.43 Tumour-associated
macrophages (TAM), whose presence is strongly associ-
ated with CRC progression, are the main source of
MMP9 in the tumour microenvironment.44 Of interest,
we previously reported elevated levels of circulating
MMP-9 in the blood of CRC patients.45 MMP-9 up-reg-
ulation alone, however, is not speciﬁc to CRC, as it has
also been reported in other malignant tumours and in
autoimmune or inﬂammatory diseases, including ulcera-
tive colitis or lymphocytic colitis.46
About 40% of the 42-gene panel was also shown to be
involved in other inﬂammatory processes (Table 3). This
observation raised the possibility that inﬂammatory con-
ditions, in particular intestinal ones, could also be
detected by our classiﬁers, resulting in a decreased speci-
ﬁcity for CRC detection. A potential risk was largely
ruled out by the observation that 91–96% of the IBD
subjects were correctly identiﬁed as controls and not as
CRC patients. The reasons for this high level of speciﬁc-
ity for CRC of our signature rich in inﬂammatory genes
are not clear at this point. It is tempting to speculate
that inﬂammatory and related genes expressed in CRC
are distinct from, or largely non-overlapping with, genes
expressed in IBD or other inﬂammatory conditions.
Importantly, none of the subjects with other type of
malignancies was misclassiﬁed, thereby conﬁrming the
speciﬁcity of the classiﬁer for CRC. The combination of
multiple biomarkers is indeed a way to palliate for pow-
erful but nonspeciﬁc information carried by single bio-
markers.
Cancer detection using a peripheral blood test is an
attractive screening method because of its simplicity in
clinical practice, which is expected to translate into
improved compliance compared with colonoscopy and
FOBT, with potential major impact in public health.
Several recent reports conﬁrmed the blood cells as a pre-
cious source of candidate gene expression markers for
cancer detection. Using a 25-gene model, Honda et al.
found a distinct gene expression proﬁle in the blood of
patients with digestive cancers compared with healthy
individuals.20 Similar results have been reported for other
type of tumours, such as breast, bladder, small cell lung
cancer and renal carcinoma.15–19 In particular, different
panels of peripheral blood biomarkers based on gene
expression have been described in recent studies to
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differentiate CRC from controls. Han et al. identiﬁed and
validated a ﬁve-gene combination that could discriminate
CRC from non-CRC samples with sensitivity and speciﬁc-
ity of 94% and 77% respectively.8 Two genes of the combi-
nation, CDA and BANK1, were also conﬁrmed to be
valuable biomarkers for CRC detection in our study. The
same group developed a seven-gene, blood-based biomar-
ker signature that could stratify subjects according to their
current relative risk to develop a CRC across a broad
range in an average-risk population.9
In spite of the promising results, this study has two
intrinsic limitations. The ﬁrst one is the small sample
size. This did not allow us to validate the signatures with
an independent set of control, cancer and adenoma sam-
ples. Internal validation methods such as non-overlapped
bootstrap have been demonstrated to be effective in
reducing the risks of model over-ﬁtting.41 However, this
risk of over-ﬁtting still exists, as this validation method
is not prospective and utilises the same sample popula-
tion used for modelling; thus, the model’s performances
might be overoptimistic. A validation study with a fully
independent data set is therefore necessary for an accu-
rate estimation of the predictor performance.47 The small
sample size also prevented us to stratify the classiﬁer
sensitivity by cancer stage. The CRC classiﬁer has been
developed starting with a slight majority of CRC stage
I-II; thus, sensitivity for the detection of early stage
CRCs is expected to be similar to the overall sensitivity.
The second limitation is that the study was not
designed to be age-matched between the control and the
case subjects. Also, patients were not recruited according
to the age criteria ﬁxed by colorectal cancer screening
guidelines and therefore patients younger than 50 year
were also included.
In conclusion, in this study, we identiﬁed in PBMC
new gene expression signatures and predictive classiﬁers
speciﬁc for colorectal cancer and adenomas. This study
provided the proof of concept that developing a mini-
mally invasive, ﬁrst intention test to screen patient with
average risk of colorectal cancer from a simple blood
draw is feasible. However, the road towards a marketable
test is still long. A large prospective multi-centric study,
which was recently concluded and included an indepen-
dent validation set, will be used to develop the test pro-
totype and to provide its clinical validation. For instance,
the two identiﬁed classiﬁers could be combined by a
decisional algorithm that release a positive or negative
binary answer to be used for the triage of average-risk
asymptomatic subjects before colonoscopy. Ultimately, a
screening study performed on a screening-eligible popu-
lation and a study comparing the ﬁnal test to a currently
used CRC screening test such as FIT is necessary to
determine the clinical utility of the test.
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